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Background. Neuromyelitis optica (NMO) attacks are poorly controlled by steroids and evolve in stepwise neurological
impairments. Assuming the strong humoral response underlying NMO attacks, plasma exchange (PLEX) is an appropriate
technique in severe NMO attacks. Objective. Presenting an up-to-date review of the literature of PLEX in NMO. Methods.W e
summarize the rationale of PLEX in relation with the physiology of NMO, the main technical aspects, and the available studies.
Results. PLEX in severe attacks from myelitis or optic neuritis are associated with a better outcome, depending on PLEX delay
(“time is cord and eyes”). NMO-IgG status has no inﬂuence. Finally, we build up an original concept linking the inner dynamic
of the lesion, the timing of PLEX onset and the expected clinical results. Conclusion.P L E Xi sas a f ea n de ﬃcient add-on therapy
in NMO, in synergy with steroids. Large therapeutic trials are required to deﬁnitely assess the procedure and deﬁne the time
opportunity window.
1.Introduction
Neuromyelitis optica (NMO) is an inﬂammatory disorder
restricted to the spinal cord and optic nerves. Contrary to
multiple sclerosis (MS), relapses of NMO are often strikingly
severe and most NMO patients present stepwise neurolog-
ical impairments. NMO treatments are aimed to prevent
the relapses with the administration of various promising
immunosuppressive drugs. However, relapse treatment is
stillatrickyproblem.Sincethelargelyusedsteroidtreatment
usually fails to control severe attacks, speciﬁc add-on treat-
ments have to be considered in order to limit the stepwise
increaseofresidualimpairment.Giventhatastronghumoral
response characterizes NMO physiology, one might assume
plasma exchange (PLEX) to be particularly well adapted in
severe NMO relapses.
We here propose to outline the rationale of the PLEX
treatment based on physiological grounds and summarize
the relevant data of PLEX studies in the setting of NMO
spectrumdisorder,assessingtheresultsobtainedineachtype
of attacks. Finally we will try to build up an original concept
linking the inner dynamic of the lesion, the timing of PLEX,
onset, and the expected clinical results.
2.Physiopathology of NMO
2.1. Pathology of NMO Lesions. A characteristic pathological
pattern has been described in NMO [1]. Lesions are inﬁl-
trated by neutrophils and eosinophils and wall capillaries are
hyalinized.Avasculocentricpatternofactivatedcomplement
and immunoglobulin of IgG and IgM types is observed that
mirrors the normal expression of AQP4. AQP4 expression
is deﬁnitely reduced in normal appearing white matter and
lost throughout the lesions. These modiﬁcations are the
hallmark of NMO and could occur alone or associated
with a wide range of lesions from mild demyelination to
large necrosis. This pattern of lesion was classiﬁed in the
pattern II of the Lassmann classiﬁcation of the inﬂammatory
lesions [1, 2]. Contrary to MS, T cells are rare in NMO
lesions and probably have no major eﬀect on the formation
of the lesions [3] .H o w e v e r ,Tc e l l sa r ep r o b a b l yi n v o l v e d
upstream in physiopathological cascade in the earlier phases2 Multiple Sclerosis International
of the disease where a complex interplay leads to anti-
gen sensitization and possibly in the initial opening of
the blood-brain barrier (BBB) [4]. Moreover, the pattern
associating vasculocentric deposition of Ig and complement,
cells (eosinophils/lymphocytes) inﬁltration and AQP4 loss is
sometimes fully dissociated from demyelination [5].
2.1.1. Speciﬁc Antibodies and Their Epitopes. The NMO-
IgG antibody is IgG1 directed against protein aquaporin-
4 (AQP4) [6]. This antibody is detected with tissue-based
immunoﬂuorescence assays with a sensitivity and speciﬁcity
for clinically deﬁned NMO of more than, respectively, 60%
and 90%. Clinically diagnosed NMO patients share clinical
common and evolutional characteristics regardless of their
NMO-IgG status. Beyond the surrogate marker value of
NMO-IgG, this marker is now used as a major diagnostic
criterion [7] and delineates the NMO spectrum disorders that
gather in a same entity both typical NMO and unusual or
truncated clinical forms [8].
AQP4 is a transmembrane protein expressed in the
apical domain of the membrane feet expansions of the
astrocytes close to the surrounded blood vessels. They are
generally found as single tetramers, closely arranged in
orthogonal arrays. This protein is critically involved in the
homeostasis of the water in the brain and interfaces with
blood vessels, especially in the clearance of free water. Loss
of perivascular AQP4 in the basal state results in cellular
swelling, ostensibly due to a failure to eliminate water
generated from cellular metabolism [9]. Thus in NMO,
since the interaction of NMO-IgG and AQP4 leads to a
functional knockout phenotype of AQP4, edema develops
as a result of functional impairment of AQP4 although
BBB is expected to be still intact, which may explain the
paradoxical lack of gadolinium enhancement in most NMO
lesions. Apart from water homeostasis, the removal of AQP4
from astrocytes membrane is associated with an impaired
homeostasis of glutamate via the loss of function of EAAT2,
a major glutamate transporter associated with AQP4 in a
macromolecular complex [10]. The disruption of glutamate
homeostasis initiates an excitotoxic mechanism damaging
oligodendrocytes and ultimately leading to demyelination
[11].
Virtually all the CNS astrocytes express AQP4, however,
some regions are enriched in AQP4. Those regions are the
spinal cord gray matter, the posterior optic nerve, the ﬂoor
of the fourth ventricle and the circumventricular organs
especially the area postrema, explaining the restriction of
the sites of lesion characterizing NMO [12]. Interestingly
circumventricular organs are also the only sites of the
CNS expressing fenestrated capillaries favoring local passive
diﬀusion of circulating antibodies.
2.1.2. NMO-IgG and Complement as Key Factors. Clinical
activity may correlate with the underlying NMO-IgG titres.
NMO-IgG detection is a strong predictor of recurrence after
an initial spinal or optic attack [13–15]. In few patients,
NMO-IgG was high during ﬂares and became negative
during the stabilized disease following treatment, and, in
contrary, an initially seronegative patient became positive
during a further attack [16, 17]. That is to say that NMO-
IgG negative sera are not always NMO-IgG negative patients
on long term. In the seminal work of Takahashi et al.
[18], NMO-IgG levels were positively correlated with both
clinical severity (i.e., blindness) and radiological severity.
Moreover,astrongpositivecorrelationwasobtainedbetween
the NMO-IgG titres at the nadir of exacerbations and the
spinal cord lesion length on MRI [18]. In contrast, low
NMO-IgG titres were observed during remission induced by
immunosuppressive maintenance therapy [14].
In vitro, the binding of NMO-IgG to the extracellular
domain of AQP4 reversibly downregulates its plasma expres-
sion.Inthepresenceofactivecomplement,thisbindingleads
to strong complement activation and rapid cell destruction.
NMO serum IgM is not AQP4-speciﬁc and abundant IgM
deposits in the NMO lesions may have passively diﬀused
after the BBB disruption by the seminal focal complement
activation initiated by NMO-IgG [19].
In an animal model of EAE with passive transfer of
NMO-IgG, the transfer exacerbated EAE signs and the typ-
ical pathological characteristics were reproduced in treated
rats [20, 21]. Direct injection of NMO-IgG in mice brains
could reproduce the pathology, but only when complement
is coinjected [22].
The NMO-IgG ability to lesion AQP4-transfected cells in
the presence of complement was assessed with serum drawn
frompatientswithmildandsevereattacks.Thepercentageof
cellslesionedbycomplementwasstronglyhigherinpresence
of sera from patients with severe attacks, although lesion
inducedbyserafrompatientswithmildattacksdidnotdiﬀer
fromnegativecontrolsorMSpatients[23].Thus,theseverity
of the disease may be partly determined by intrinsic NMO-
IgG characteristics to activate the complement.
2.2. Proof of Concept of PLEX in NMO. As we already
described, NMO lesions are associated with a strong IgG,
IgM and complement deposition, typical of the pattern II
in the Lassmann classiﬁcation. The NMO-IgG is involved
in a complement-dependant toxicity against the astrocytes.
All of these components—IgG, IgM, and complement—are
targeted by plasma exchanges. By means of 5 exchanges, all
the exchanged molecules will drop to less than 20% of their
initiallevel[24,25].Bythisway,antibodiesandcomplement,
which are the core of the pattern II lesions, are excluded
fromthecirculating pool and cannotmigrate anymoreto the
lesions.
Although PLEX has long been used in various demyeli-
nating disorders [26], there is some clue that the pattern is a
key determinant of PLEX eﬃciency. In a retrospective study,
Keeganetal.[27]reportedthatallthepatientssuﬀeringfrom
demyelinatingdisordersandimprovedbyPLEXhadabiopsy
proven pattern II lesion. None of the patients with any other
kind of lesion improved. However all these patients were MS
without NMO-IgG and none were NMO [28].
All the aforementioned ﬁndings stress that circulating
NMO-IgG and complements are the two main actors of theMultiple Sclerosis International 3
NMO pathogeny and why clearing them from blood with
PLEX should be appropriate for special beneﬁts.
3.PlasmaExchangeProcedure
3.1. Principles and Goals. PLEX or plasmapheresis is the
ﬁltration of the plasma, which is removed, replaced by
artiﬁcial plasma and reinfused to the patient—the plasma
exchange. Basically, the goal of the ﬁltration step is to remove
a given volume of patients plasma and to return an artiﬁcial
plasma substitute in its place [24].
3.2. Technique. PLEX is carried on in a nephrology or a
resuscitation ward. Two high ﬂow rate accesses are manda-
tory: an input line from patient to device (“artery”) and a
return line from device to patient (“vein”). In continuous
ﬁltration, two needles are placed in both arms or groins
in order to drawn out the blood of the body through an
extracorporeal line connected to one needle, then blood
is processed and reinfused continuously through the other
needle.Incaseofdiscontinuousﬁltration,theseparationand
remixing are done in small batches through a single venous
access in the groin where in and out cycles may alternate.
Anticoagulation (citrate or heparin) is added to the blood
preplasmaﬁltertopreventfromclotting.Theremovedblood
is processed (apheresis procedure) in a cell separator that
continuously separates plasma from cellular components
(consisting of red and white blood cells and platelets)
either by a centrifugation ring with permanent in and out
ﬂow, or by ﬁltration through a porous membrane. Small
molecules like cytokines as well as large molecules, such as
albumin and immunoglobulin, are easily extruded from the
bloodcompartmentwithareported sievingcoeﬃcient >0.95
at a blood ﬂow rate of 100mL/min. The cleared cellular
components are then combined with the replacement ﬂuid
(donor plasma or artiﬁcial albumin mixed with a saline
solution) and returned to the patient through the needle in
the other arm. A PLEX session is usually performed in 2 to 6
hours, depending on patient’s height, weight, viscosity of the
blood, and technical parameters.
3.3. Kinetics of the Target Exchanged Components. All the tar-
geted components are distributed in the interstitium (extra-
vascular compartment) by variable part. Large molecular
weight compounds equilibrate slowly between the vascular
spaceandtheinterstitium.Therelationcurveoftheachieved
concentration of a plasma component (C) after a unique
exchange of a given plasma volume is exponential inverse,
following a single kinetics. The larger volume of plasma
exchanged during each session clears a larger amount
targeted circulating component. An exchange of one body
plasma volume leads to the immediate clearance of 50%
of the circulating component. A 1.3 body mass volume
exchange that removes about 72% of the concentration is
generally agreed. Beyond, the volume to process increases
massively for too little gain.
However, according to the distribution of C in the inter-
stitium,theachievementoftheclearanceofCwillnecessitate
the use of multiple PLEX sessions separated by the time
necessary for the equilibration of C concentration between
interstitium and vascular spaces. The number and frequency
of sessions should be evaluated according to the biological
characteristics of the components to remove (synthesis
level, vascular distribution, diﬀusion ability). An empirically
driven number of 4 to 6 sessions is usually scheduled. The
durability of the immunomodulatory eﬀect after PLEX is
diﬃcult to assess and will depend on the turnover rate of
the targeted humoral components. Concomitant intensive
immunosuppressive therapy (i.e., steroids, mitoxantrone,
mycophenolate mofetil, and rituximab) will be required to
sustain the obtained depletive eﬀect.
3.4. Risks and Side Eﬀects. PLEX are contraindicated in case
of ongoing infectious disease, precarious hemodynamics,
and active hemorrhage (heparin). Immediate side eﬀects are
related to the extracorporeal line: hemodynamic instability,
vasovagal syndrome, numbness or tingling, venous puncture
hazards with excessive local bleeding, septicaemia, or allergy.
Since blood coagulation factors are all depleted by PLEX,
hemostasis is aﬀected in variable ways: ﬁrst, a hypocoagu-
lation state is immediately achieved by the global depletion
of all the coagulation factors for half a day; at day 2, short-
life procoagulant factors are regained but antithrombin-III
synthesis is delayed leading to a hypercoagulable state until
day 3. Preventive, anticoagulation with heparin is always
required since the high risk of thrombosis. Persistently low
ﬁbrinogen levels have been described with the concomitant
use of high dosage steroid infusion. In summary, PLEX
is generally well tolerated and now commonly and safely
used.
3.5. PLEX and Steroids. Methylprednisolone pharmacoki-
netics is characterized by a very short half-life (about 2
hours) and although steroid binding to plasma protein is
about 75%, the volume of distribution is very large (about
1.5L/kg) [29]. These factors are the key of the negligible
PLEX eﬀect upon steroids biodisponibility [30, 31]. Of note,
all the relapses received steroids. When used the same day
as PLEX procedure, steroids were infused at the end of each
PLEX session.
4. PLEX in Severe Attacks
Various regimens of high doses of intravenous methyl-
prednisolone are used in ﬁrst line of treatment ranging
from 3g infused in 3 days, to 10g in 5 to 10 days,
depending on authors. There is no evidence in favor of one
r e g i m e no ra n o t h e ra n de ﬃcacy assessment has never been
addressed. Moreover, even if steroids reduce the inﬂamma-
tory cellular response by triggering apoptosis of lympho-
cytes, they are clearly not suﬃcient because poor outcomes
are still a common issue even when steroid treatment is
given immediately after onset. We wish to develop here
the evidence for the eﬀectiveness of PLEX that we have
been largely using as an add-on therapy for more than
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Table 1: Disability measured as EDSS during spinal attacks stratiﬁed with basal impairment. St: steroid-only-treated group; St+PE: steroid-
and PE-treated group. Values are given as mean (SD) (from [37]).
Basal EDSS (null) Basal EDSS (1.0 to 5.5) Basal EDSS (≥6.0)
St St + PE P St St + PE P St St+ PE P
(n = 17) (n = 7) (n = 26) (n = 13) (n = 24) (n = 9)
Basal EDSS 0 (0) 0 (0) 0.99 3.9 (0.8) 3.9 (1.6) 0.59 7.4 (1.0) 7.1 (0.8) 0.52
Acute EDSS 7.1 (1.5) 7.6 (1.2) 0.52 7.6 (1.3) 7.6 (1.1) 0.67 8.9 (0.9) 8.6 (0.6) 0.24
Residual EDSS 5.9 (1.9) 2.1 (1.9) <0.01 5.8 (1.6) 5.1 (1.1) 0.21 8.5 (1.1) 7.6 (1.0) 0.05
ΔEDSS 5.9 (1.9) 2.1 (1.9) <0.01 2.0 (1.5) 1.2 (1.6) 0.10 1.1 (0.8) 0.5 (0.8) 0.11
4.1. Spinal Attacks. PLEX proved to be eﬃcient in central
demyelinating diseases in a randomized sham-controlled
study [32, 33]. Keegan et al. [26] reviewed the clinical
data from 59 patients who received PLEX for inﬂammatory
demyelinating diseases, including 10 NMO and 6 acute
transverse myelitis (ATM) cases. A moderate or marked
improvementwasobtainedinhalfofNMOandATMpatient
groups. The late ﬁnal outcome at one year was more or
less obtained during the ﬁrst month after treatment in both
groups, without regard to success or failure of treatment [26,
34]. A small number of case reports and few small studies
were reported with variable issues. Judging improvement is
even more complex due to the subjective classiﬁcation of
improvement in mild/moderate/marked instead of a quanti-
ﬁed clinical exam [26, 34–36]. Moreover the natural history
of single spinal relapse in NMO has never been addressed,
so any improvement bias after PLEX is inappreciable in the
absence of a control group. Finally, most authors used PLEX
as a rescue treatment given late after the onset. For example
PLEX was delayed from onset by a mean of 33 ± 30 days in
Brunot et al. [34] and a median of 30 days (6 to 90 days) in
Llufriu et al. [35].
Although a synergistic eﬀect of steroids and PLEX was
long expected due to their complementary action, none of
these studies compared conventional steroid treatment alone
with add-on PLEX-treated attacks.
We previously reﬁned these results in a study of outcome
after severe spinal attacks associated with NMO spectrum
disorders [37]. We included 96 spinal attacks from 43
patients, divided in two groups: (1) a steroid-only group
designed from historical patients treated with steroids alone;
(2) an active group treated with both PLEX and steroids.
Steroidinfusionwasstartedimmediatelyafterpatientadmis-
sion. PLEX decision was raised at the same time and started
as soon as possible during the two days later. As a major
diﬀerence with other groups, PLEX was never initiated as a
delayed rescue treatment after a standard steroid treatment
failure. Since PLEX therapy is mainly expected to minimize
residual impairment, we used the ΔEDSS (calculated as the
diﬀerence between residual and basal EDSS) as the main
outcome.
If we except 5 PLEX delayed due to diﬃcult medevac
reasons, PLEX was initiated by a mean of 5.4 ± 3.1d a y s
after attack onset with a median of 4 sessions. There was no
signiﬁcant diﬀerence between the PLEX-treated and steroid-
only groups for basal and acute EDSS (3.9 ± 2.9v e r s u s
4.2 ± 2.9,and7.9 ± 1.0v ersus8.0 ± 1.4;P = NS),however,
residual EDSS (5.1 ± 2.4v e r s u s6 .8 ± 1.9, P<0.01) and
mean ΔEDSS (1.2 ± 1.6v e r s u s2 .6 ± 2.4, P<0.01) were
signiﬁcantly lower in the PLEX-treated group than in the
steroid-only group.
Basal EDSS dramatically inﬂuenced therapy outcome
(Table 1). During the ﬁrst attack, although acute EDSS were
similar in both groups (7.6 ± 1.2v e r s u s7 .1 ± 1.5, P = NS),
ΔEDSS and residual EDSS were dramatically reduced in the
PLEX-treated group (2.1 ± 1.9v e r s u s5 .9 ± 2.0, P<0.01)
given that acute EDSS was similar in this sub-group. In the
two other sub-groups of basal impairment (EDSS 1.0 to 5.5
and EDSS ≥ 6.0 ) ,r e s i d u a lE D S Sa n dΔEDSS tended to be
lower in PLEX-treated attacks but no statistical signiﬁcation
could be obtained due to the small size of these groups.
The classical Lazarus eﬀect, deﬁned as a very short-
term dramatic improvement [38], was rather unusual in
our group but our study was not designed to analyse
short-term improvement. The patients who experienced this
eﬀect have all received a very early treatment (less than 2
days). However, in Maga˜ na et al.’s paper [39], patients who
exhibited functional improvement did so within a median of
4 days (third PLEX), although a minority (6%) exhibited a
delayed response (more than 2 months).
Minor side eﬀects occurred in 24% of PLEX-treated
attacks and resulted in PLEX interruption once (84-year-old
patient with pulmonary embolism).
In summary, PLEX-treated patients achieved a signiﬁ-
cantly better outcome after a spinal attack, especially if PLEX
was given during the ﬁrst attack. The exact eﬀect of PLEX
in previously impaired patients should be validated in a
largermulticentriccohort.AsPLEXprovedtobeapromising
treatment in spinal attacks, it would now be unethical to
design a study with a sham-treated control group.
Predictors of good outcome were studied in a large group
of PLEX including 26 NMO patients [37]. The only good
outcome predictor was normal or brisk reﬂexes in acute
phase [39]. Surprisingly a short PLEX delay was associated
with a good outcome in a ﬁrst study [26]b u th a dn oe ﬀect
in a second study, although one should remind that median
PLEX delay was long (23 days) in this later compared to
our group. The same PLEX response rate was obtained
irrespective of NMO-IgG serostatus in our cohort and in the
Mayo Clinic cohort [39].
As a practical consequence, faced with a patient suﬀering
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should not be required to start PLEX as soon as possible,
since PLEX was found eﬃcient in NMO-IgG negative
patients.
4.2.OpticAttacks. VisualimpairmentinNMOisverysevere.
Wepreviouslyshowedthatanimmediateunilateralblindness
occurred in a third of patients after the ﬁrst optic neuritis
(ON), and generally two attacks are suﬃcient to cause a
deﬁnitive loss of vision [40]. Few PLEX were undertaken
after ON and a quick dramatic recovery is usual as we also
observed [41, and unpublished results]. Depending authors,
PLEX were used immediately [41] or as a delayed add-on
therapy [42–45]. After pooling severe (acute visual acuity <
1/10◦) ON patients (either NMO or in the NMO spectrum)
fromavailablestudies[41,42,45,46]withours(unpublished
results), data were gathered for 39 eyes. PLEX were given in
a median of 19 days in patients who recovered a visual acuity
more than 1/10◦ (considered here as a treatment success) but
41 days in treatment failure. A clear eﬀect of PLEX delay was
observed since success rate was 8/8 (100%) during the ﬁrst
11 days, then 4/7 (57%) from days 12 to 22, and 7/13 (53%)
from days 23 to 73. Moreover, even when patients recovered,
averaged residual VA tended to be lower in delayed PLEX
patients. Interestingly, the spontaneous recovery (>1/10◦)
after severe ON treated by steroids alone was about 40% in
our cohort (from [40]), which is very close to the recovery
obtained in the two last groups of late PLEX. In conclusion,
strongcluessupportthatPLEXchangetheoutcomeofsevere
ON only when they are given early, however broader studies
usingcarefullychosenpatientsarestilllackingtoconﬁrmthis
hypothesis.
4.3. Brain Attacks. Apart from opticospinal attacks, severe
brain attacks are described in NMO, especially involv-
ing hypothalamus and medulla oblongata. Those lesions
are usually severe and associated with blindness, central
endocrine disorders, or quadriplegia with respiratory failure.
Nonspeciﬁctelencephaliclesionsarecommonbutaremostly
asymptomatic [47]. However, symptomatic lesions involving
supratentorial white matter are exceptional and extensive
[47]. Even if a favourable outcome after PLEX has been
reported in a few severe cases [48, 49], comparative data are
still lacking.
Posterior reversible encephalopathy syndrome (PRES) is
an encephalopathy with consciousness and visual distur-
bances with rapidly reversible changes on MRI consistent
with vasogenic edema. PRES are triggered by blood pressure
instability or ﬂuid stresses due to various causes. It seems
to occur more often than coincidental in NMO patients: 5
out of 70 consecutive NMO-IgG patients evaluated at Mayo
Clinic [50]; 2 out of 5 in Hadassah Medical School, Israel
[51]. Authors proposed that the autoimmune-mediated dis-
ruptionoftheAQP4waterchannelfunctionmaypredisposes
to PRES at comparable levels of acute illness [50]. PLEX was
involved as a trigger in one case with a good ﬁnal outcome
[50]. In few cases, PLEX were implemented as curative
treatment with an overall good outcome [50, 51].
5. Timingof PLEX: Evolvingto a KeyConcept
Besides knowing PLEX are eﬀective and safe, the central
question remains: is PLEX necessary as soon as and as often
as possible? Prospective, randomised, multicentre clinical
trials would be required to deﬁnitively answer the question.
For most authors, to date PLEX are considered as an add-
on rescue treatment after steroid failure. The European
recommendation from EFNS is to start with an early steroid
course no matter the severity [52]. Early escalation with
PLEX is only recommended after a failure of a second
course of steroids, that is to say that PLEX initiation may be
postponed for more than a week.
As we demonstrated before, PLEX eﬃciency depends on
the timing of initiation, ranging from immediate dramatic
improvement (the Lazarus eﬀect)t on oe ﬀect according to
whether they are given early or very late. We propose to
regress to the dynamic of the inﬂammatory NMO lesions
to explain why PLEX eﬃciency is strongly dependant of the
timing of their onset.
5.1. Evidence for Reversible Dysfunction Preceding Irreversible
TissueLoss. Aswedescribedabove,lesionistheconsequence
of a cascade of reversible events, susceptible to an external
action. One could abruptly divide this cascade into two
main points: (1) ﬁrstly, the binding of NMO-IgG to AQP4
triggers the functional impairment of astrocytes, quickly
completed by a complement-mediated cell destruction; (2)
the dysfunction of EAAT2 transporters, as a bystander eﬀect,
impairs the clearance of free glutamate which progressively
accumulates and initiates an excito-toxic mechanism upon
oligodendrocytes, ultimately leading to oligodendrocytes
apoptosis and demyelination [11, 53]. This excito-toxicity is
reversed in vitro by adding a competitive antagonist of the
NMDA receptor [11].
The time sequence of these events was studied in lesions
induced by direct mouse brain injection with NMO-IgG
and complement [22]. Loss of AQP4 and GFAP, and myelin
breakdown were evident 7h following the injection. The
inﬂammatory cells inﬁltration became evident later. Within
12h, axonal injury became prominent. By day 7, axonal loss
and dying neurons were evident. Finally, one could suppose
thataveryearlyinterventiontargetingastrocytesdysfunction
may prevent the progression to the bystander eﬀect.
5.2. Evidence Supporting an Early Treatment. The inﬂuence
of treatment delay upon outcome has been addressed in a
singlestudyofﬁrstONreceivingsteroidtreatments[54].The
outcomeswerebothvisualacuityandthewidthoftheretinal
ﬁberslayerevaluatedwithoptictomography(OCT).Patients
were divided into two groups: one group with a good visual
outcome, including a high residual visual acuity and high
RFL; a second group with a poor visual outcome in terms
of low acuity and low RFL. Very interestingly, the two groups
were similar in all the parameters except one: patients with a
goodoutcomereceivedsteroidswithalowermeandelayafter
ON onset, by a mean of 1.8 ±1.1d a y sc o m p a r e dt o7 .8±3.8
days in patients with a poor outcome. This study is the ﬁrst6 Multiple Sclerosis International
Hours Days Weeks
Hours Days Weeks
Lesion dynamics
Oedema
Astrocytes
Oligodendrocytes
Neural tissue
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Figure 1: Hypothetical correlation of lesion stages and PLEX eﬀect. The dynamic of the lesion is staged according to pathological data.
Clinical and radiological outcome is linked to the delay of PLEX onset.
proof that a delayed infusion of steroids is associated with a
pooreroutcome.Asimilareﬀectoftreatmentdelay,although
unknown, should be expected in spinal attacks.
In spinal attacks treated with PLEX, early initiation of
treatment was one out of the predictors of good outcome
[26]. In a larger study encompassing attacks from various
demyelinating disorders, success rates were stratiﬁed by
delay: improvement occurred in 83% when given before
d a y1 5 ,b u tf e l lt o4 3a f t e r2m o n t h s[ 35]. Moreover
the dramatically very short-term improvement, called the
Lazaruseﬀect[38],issometimesobservedaftersevereattacks
receiving a very early treatment with PLEX and steroids.
However, this earliness responsibility on the Lazarus eﬀect
remains elusive since no study is available on this rather
unusual eﬀect.
5.3. Lesion Stages and PLEX Action: “Time Is Cord and Eyes.”
In the light of the available data, we postulate a link between
the staging of NMO lesion and the PLEX eﬀect upon clinical
and radiological outcome (Figure 1). Stage 1 (ﬁrst hours):
acute attack provokes for hours an astrocyte dysfunction
(by NMO-IgG binding on AQP4 leading to internalization)
mainly expressed by an edema. This purely edematous lesion
could be immediately reversible by the clearance of NMO-
IgG preventing the loss of astrocytes and the excitotoxic
cascade. Clinical and radiological recovery after PLEX is
dramatic and explains the Lazarus eﬀect. Stage 2 (days):
the underexpression of EAAT2 induces an excitotoxic eﬀect
of glutamate on oligodendrocytes leading progressively to
demyelination and axonal loss. Astrocytes loss initiates a self-
sustained excitotoxic process henceforth independent from
NMO-IgG persistence. Even if the extraction of NMO-IgG
and complement by PLEX ends the astrocytes aggression.
A variable amount of them has been already lost and exci-
totoxic eﬀects upon oligodendrocytes are evident. Variable
amount of tissue is lost as visible on MRI and recovery is
incomplete. S t a g e3( w e e k s ) :atrocytes, oligodendrocytes, and
axonallossareprominent,engulfedinlargeareasofnecrosis.
PLEX is almost useless. Neural tissue remains cavitated or
atrophic on MRI and no recovery will be expected.
We propose to reconsider PLEX as a major part of the
treatment of severe NMO attacks and suggest that PLEX
could be given systematically in severe relapses of NMO,
extended transverse myelitis or bilateral severe ON resistant
to steroids. Moreover, when given they should be started as
soon as possible with steroids.
6. PLEX as Preventive Treatment
Since NMO-IgG positivity is both predictive of attacks and
severity, achieving a low concentration of plasmatic antibod-
ies remains a goal to achieve. Besides immunosuppressive
drugs, weekly PLEX have been used to achieve a sustained
depletion of NMO-IgG and complement. Favourable cases
have been reported but large studies are lacking [55].
Miyamoto and Kusunoki [55] proposed to use PLEX asMultiple Sclerosis International 7
preventive treatment as an add-on therapy after immuno-
suppressive drugs failure.
7.PreventiveTreatmentsandFutureAvenues
The natural history of NMO leads all the patients to a deep
impairment in a stepwise fashion without progressive phase.
In our study, 5 years after the onset, 70% of patients suﬀered
from a unilateral loss of vision and almost half of them
from a bilateral loss of vision [40]. After 8 years, half of the
patients had suﬀered from a severe myelitis and had become
chairbound [13]. The mortality rate was very high before
immunosuppressive drugs but dramatically dropped since
they are largely used [56]. The exact role of recurring PLEX
along the remaining attacks to tune the outcome to a low
impairment has not yet been addressed but remains most
probable considering this striking epidemiological change
of mortality in French West Indies. Immunosuppressive
drugs are necessary to prevent further relapses but no
recommendation is yet available concerning therapeutic
escalation.
Since the lesion severity mostly depends on the initial
and deﬁnitive depth of the loss of AQP4 and astrocytes,
future treatments strategies may be directed upon AQP4
preservation. Small molecules or monoclonal antibodies
could be used to prevent NMO-IgG binding to AQP4 and to
blockthephysiopathologicalcascadeupstream[57].Another
strategy may deplete pathogenic antibodies by apheresis
using dedicated immunoadsorption systems as previously
described in myasthenia gravis [58] and in various extra
neurological disorders [59]. However, if the value of this
technique is less clear in disorders like MS [60, 61], where
pathology is broader than a speciﬁc antibody, it could be
especially suitable to NMO since anti-AQP4 seems to be
the pathological core. The strength of these techniques is
the speciﬁcity of the antigenic absorption with no regard to
the class or subclass of antibodies and no ﬂuid replacement
[59]. No experience is yet available in the NMO setting.
Lymphocytapheresis was successfully described in isolated
cases of resistant attacks [62–64]. This alternative therapy
may be considered in PLEX-resistant relapses and should be
better studied in severe relapses as an alternative of steroids
and PLEX. A complementary approach may target the
complement system with newly developed anticomplement
recombinant antibodies at various levels, with preliminary
promising results [22]. Such future treatments may be aimed
at preventing or curing the attacks.
8. Conclusion
PLEX,insynergywithsteroids,couldbeamajortreatmentof
relapses, aimed at preventing cumulative disability. PLEX is a
safeandeﬃcientadd-ontherapyinNMO.Thesepreliminary
results suggest that PLEX may modify the short prognostic
of NMO relapses, as long as given early. PLEX proved to be
eﬀective regardless of NMO-IgG status.
Animal models have conﬁrmed that mechanisms leading
tolesionevolveoverhoursanddays.Thosemodelsshouldbe
able to conﬁrm that early therapeutic intervention directed
to halt the ongoing lesions should be even more dramatic in
an early narrow therapeutic window.
Thenextstepsshouldbetoconcentrateuponlargemulti-
centric therapeutic trials in order to validate the therapeutic
procedure and to determine the time opportunity window.
However, we are aware that good trials against placebo
could now be diﬃcult to accept since this is an extremely
devastating disease.
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